Afamitresgene Autoleucel

Definition

A preparation of autologous human T-lymphocytes transduced with a lentiviral vector encoding an affinity-enhanced T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A2-restricted peptide human melanoma antigen A4 (MAGE-A4) C1032, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, afamitresgene autoleucel targets and binds to tumor cells expressing MAGE-A4. This results in cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen (TAA) MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types.

Also known as ADP-A2M4, Afami-cel, AFAMITRESGENE AUTOLEUCEL, Autologous Genetically-modified MAGE-A4 C1032 T Cells, Autologous Genetically-modified MAGE-A4 C1032 T Lymphocytes, MAGE-A4 SPEAR T-cells, MAGE-A4C1032T, SPEAR T-cell ADP-A2M4, Tecelra — per NCIT

Also identified as

• NCIT NCIT:C175738 per NCIT
• UNII CUY18BJ7BP per RXNORM

Indications